Immune Aging and Immunotherapy in Cancer

Immune Aging and Immunotherapy in Cancer

Immune functions decline as we age, while the incidence of cancer rises. The advent of immune checkpoint blockade (ICB) has not only revolutionized cancer therapy, but also spawned great interest in identifying predictive biomarkers, since only one third of patients show treatment response. The agin...

Full description

Bibliographic Details
Main Authors:	Melanie Kaiser, Maria Donatella Semeraro, Markus Herrmann, Gudrun Absenger, Armin Gerger, Wilfried Renner
Format:	Article
Language:	English
Published:	MDPI AG 2021-06-01
Series:	International Journal of Molecular Sciences
Subjects:	T cells aging cancer immune checkpoint inhibitors biomarker senescence
Online Access:	https://www.mdpi.com/1422-0067/22/13/7016

Similar Items

Senescence and Aging: Does It Impact Cancer Immunotherapies?
by: Damien Maggiorani, et al.
Published: (2021-06-01)

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
by: Sacha Gnjatic, et al.
Published: (2017-05-01)

VISTA: A Promising Target for Cancer Immunotherapy?
by: Tagliamento M, et al.
Published: (2021-06-01)

Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
by: Muhammad Umair Mushtaq, et al.
Published: (2018-07-01)

Predictive biomarkers for tumor immune checkpoint blockade
by: Tong M, et al.
Published: (2018-10-01)

How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma
by: Giulia Martini, et al.
Published: (2021-09-01)

Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
by: Barbara Seliger
Published: (2019-05-01)

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment
by: Tao Jiang, et al.
Published: (2020-06-01)

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01)

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies
by: Maria Silvia Cona, et al.
Published: (2019-02-01)

Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives
by: Daniel M. Girardi, et al.
Published: (2021-12-01)

Correlation between patients’ age and cancer immunotherapy efficacy
by: Qiong Wu, et al.
Published: (2019-04-01)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
by: Yuqing He, et al.
Published: (2021-09-01)

Immunotherapy in Metastatic Colorectal Cancer: Could the Latest Developments Hold the Key to Improving Patient Survival?
by: Emmanouil Damilakis, et al.
Published: (2020-04-01)

Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy
by: Lisa K. Puntigam, et al.
Published: (2020-07-01)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
by: Rilan Bai, et al.
Published: (2020-08-01)

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
by: Busra Isik, et al.
Published: (2021-04-01)

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
by: Magdalena Olbryt, et al.
Published: (2020-06-01)

Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
by: Elisabet Cuyàs, et al.
Published: (2020-07-01)

A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies
by: Tyler J. Nielsen, et al.
Published: (2021-03-01)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
by: Miren Zuazo, et al.
Published: (2020-11-01)

Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer
by: Daniele Raggi, et al.
Published: (2021-08-01)

Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer
by: Eiko Hayase, et al.
Published: (2021-06-01)

Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2020-07-01)

Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy
by: Shumin Yuan, et al.
Published: (2020-10-01)

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
by: Katarzyna Tomela, et al.
Published: (2020-09-01)

Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2020-01-01)

Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer
by: Maria Adamaki, et al.
Published: (2021-01-01)

Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice
by: Hui-Ching Wang, et al.
Published: (2020-10-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
by: Ho Jung An, et al.
Published: (2021-08-01)

Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients
by: Ana Callejo, et al.
Published: (2021-06-01)

Immune Checkpoint Inhibitor–Related Cardiovascular Toxicity in Lung Cancer
by: Lova Sun, MD, et al.
Published: (2019-12-01)

The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
by: Amy L. Cummings, et al.
Published: (2017-08-01)

Transcriptional Regulation of Cancer Immune Checkpoints: Emerging Strategies for Immunotherapy
by: Simran Venkatraman, et al.
Published: (2020-12-01)

Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop
by: Ariel E. Marciscano, et al.
Published: (2018-01-01)

An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma
by: Shen YC, et al.
Published: (2021-07-01)

Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
by: Shixiang Wang, et al.
Published: (2019-09-01)

Immunotherapy for Uterine Cervical Cancer
by: Masahiro Kagabu, et al.
Published: (2019-09-01)

Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy
by: Imerio Capone, et al.
Published: (2018-03-01)